Uncategorized

The LRA and our clinical arm Lupus Therapeutics are pleased to share good news from Cabaletta Bio, Inc. that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for CABA-201, a CAR T cell investigational therapy in development to treat systemic lupus erythematosus and lupus nephritis – a common lupus complication causing … Investigational CAR T Cell Gets Fast Tracked by U.S. FDA

We are excited to share good news – our Lupus Clinical Investigators Network, LuCIN, managed by LRA’s affiliate Lupus Therapeutics, will be working on a new research project to increase diverse representation of patients in lupus trials to be funded with a $500,000 National Institutes of Health Innovation Award from the Food and Drug Administration’s … NIH Awards $500,000 to Advance to Advance Diversity in Lupus Trials

We are pleased to share positive results from the two-part Phase 2 LILAC study published in the New England Journal of Medicine showing that the investigational therapy litifilimab (BIIB059) lessened skin disease activity in cutaneous lupus erythematosus. There is a great unmet need for people with cutaneous lupus, a type of lupus with few treatment options that … New England Journal of Medicine Publishes Positive Data of Litifilimab in Cutaneous Lupus Erythematosus

Advocating for your own best care includes raising the possibility of joining a clinical trial with your healthcare provider.  Here’s more on how: It is important for individuals who are considering participation in a trial to understand what will be involved.  The National Institutes of Health (NIH) asking the healthcare team overseeing the study about … Ask About Clinical Trial Opportunities

Up to 95% of lupus patients report pain and fatigue caused by the disease. To explore ways to fix this, a research team led by Dr. Cynthia Aranow at The Feinstein Institutes for Medical Research studied whether lessening inflammation in patients with lupus would also lessen pain and fatigue. In this study, she and her … LuCIN Investigators Show that Stimulating the Vagus Nerve in Lupus Patients Decreases Pain and Fatigue

Results of clinical trials testing potential lupus treatments were highlighted at the American College of Rheumatology’s annual meeting ACR Convergence 2020. These studies include phase I trials, which test for side effects and a safe dosage; larger phase II trials, which test for effectiveness and further gauge safety; and large phase III trials, which confirm … Promising New Lupus Treatments Highlighted ACR Annual Meeting

PPD, Inc. issued a press release  today announcing its collaboration with the Lupus Research Alliance affiliate Lupus Therapeutics to optimize lupus clinical research among its pharmaceutical and biotech clients. As a contract research organization, PPD helps its clients design and implement clinical trials. PPD expects to gain from Lupus Therapeutics’ deep clinical trial design expertise … Lupus Therapeutics Collaborating with PPD to Accelerate Lupus Clinical Research

Videotape of 8.24.20 Learn from Lupus Zoom Webcast Ensuring the clinical trial process is accommodating for participants has always been the goal. However, COVID-19 has forced industry, research organizations, doctors, and patients to think twice about the process and its impact on high-risk populations including people with lupus who are immunocompromised. In light of COVID-19, … Watch Webcast Video: Redefining Lupus Trials Amid COVID-19 and Beyond

African-Americans are more likely to develop lupus than Caucasians, but less likely to take part in clinical trials of the disease. However, a new study showed that several simple steps, such as providing transportation and flexible scheduling, may allow more African-Americans to participate in trials. The study was conducted by top lupus experts including Dr. … New Study Presents Strategies That Helped African-Americans Take Part In Lupus Trials